{"disease":{"id":"noonan-syndrome","name":"noonan syndrome"},"drugs":{"marketed":[{"drug_id":"somapacitan-beco","indication_name":"Growth failure associated with Noonan syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"SOGROYA","generic_name":"SOMAPACITAN-BECO","company_name":"NOVO NORDISK INC","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"somapacitan","indication_name":"Growth failure associated with Noonan syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sogroya","generic_name":"SOMAPACITAN","company_name":"Novo Nordisk","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Sogroya works by binding to the growth hormone receptor, mimicking the action of growth hormone and stimulating growth and development."},{"drug_id":"oxymesterone","indication_name":"Noonan's syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Anamidol","generic_name":"OXYMESTERONE","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"oxymesterone","quality_score":null,"revenue":null,"mechanism":"Anamidol binds to androgen receptors in the body, triggering a cascade of downstream effects that promote muscle growth and development."},{"drug_id":"fluoxymesterone","indication_name":"Noonan's syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fluotestin","generic_name":"FLUOXYMESTERONE","company_name":"","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen","quality_score":10,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00960128","title":"Observational Prospective Study on Patients Treated With Norditropin®","phase":"","overall_status":"COMPLETED","enrollment_count":21249,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT03050268","title":"Familial Investigations of Childhood Cancer Predisposition","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT07336394","title":"Precision Diagnosis and Risk Stratification of Rare Cardiomyopathies Based on Novel Cardiac Magnetic Resonance Techniques","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Chinese Academy of Medical Sciences, Fuwai Hospital","has_results":false},{"nct_id":"NCT04463316","title":"GROWing Up With Rare GENEtic Syndromes","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"dr. Laura C. G. de Graaff-Herder","has_results":false},{"nct_id":"NCT04888936","title":"Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06938542","title":"Palliative Care Needs of Children With Rare Diseases and Their Families","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":480,"lead_sponsor_name":"Children's National Research Institute","has_results":false},{"nct_id":"NCT05330325","title":"A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":412,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT05308927","title":"French Registry of Children Treated With Norditropin® for Short Stature Associated With Noonan Syndrome","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":221,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT07464821","title":"National Multicentre Study on Lipid Profile in Noonan Syndrome and Related Disorders: Trends by Age, Gender and Genotype","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT06355622","title":"Prevalence and Characterization of Pain in RASopathies","phase":"NA","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT06331117","title":"Effect of RAS/MAPK Pathway Hyperactivation on Growth' and Bone' Profile of the RASopathies","phase":"NA","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT05202210","title":"Constitution of a Biological Collection to Study the Pathophysiology in Noonan Syndrome","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"University Hospital, Toulouse","has_results":false},{"nct_id":"NCT05761314","title":"Solid Tumors in RASopathies","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT06550635","title":"Joint and Hematologic Disorders of Noonan Syndrome: French Descriptive Cross-sectional Study","phase":"","overall_status":"COMPLETED","enrollment_count":71,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT03435627","title":"Post Marketing Surveillance on Long-term Use With Norditropin® (Short Stature Due to Noonan Syndrome)","phase":"","overall_status":"COMPLETED","enrollment_count":71,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT05361811","title":"Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial","phase":"NA","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02713945","title":"Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":53,"lead_sponsor_name":"University Hospital, Toulouse","has_results":false},{"nct_id":"NCT01927861","title":"Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":51,"lead_sponsor_name":"Novo Nordisk A/S","has_results":true},{"nct_id":"NCT05723835","title":"A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":47,"lead_sponsor_name":"Novo Nordisk A/S","has_results":true},{"nct_id":"NCT06555237","title":"MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathies","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Medical University of Warsaw","has_results":false},{"nct_id":"NCT06267807","title":"Lymphatic Phenotype in Noonan Syndrome Spectrum Disorders","phase":"NA","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"Radboud University Medical Center","has_results":false}],"total":21},"guidelines":[],"source":"Drug Landscape verified database"}